Priothera lands Series A

Dublin, Ireland-based Priothera Limited, a developer of orally applied sphingosine 1 phosphate receptor modulators for haematological malignancies, has secured 30 million euros in Series A financing.

ByIris Dorbian

12 October 2020•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Deals Healthcare Briefs

Priothera lands Series A

Fountain Healthcare Partners

HealthCap

Related articles